Holen Sie sich die Stockscreener-App
33.47
3.27%
-1.13
Vorhandelsmarkt:
33.47
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$34.60
Offen:
$34
24-Stunden-Volumen:
1.41M
Relative Volume:
0.92
Marktkapitalisierung:
$3.23B
Einnahmen:
$610.16M
Nettoeinkommen (Verlust:
$-532.93M
KGV:
-6.0539
EPS:
-5.5287
Netto-Cashflow:
$-442.30M
1W Leistung:
-5.21%
1M Leistung:
+7.24%
6M Leistung:
-14.83%
1J Leistung:
-34.36%
1-Tages-Spanne:
$32.94
$34.96
1-Wochen-Bereich:
$32.94
$35.95
52-Wochen-Spanne:
$25.81
$53.47
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
33.47 | 3.33B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Can Ultragenyx Pharmaceutical Inc. rally from current levelsM&A Rumor & Safe Entry Trade Reports - newser.com
Will Ultragenyx Pharmaceutical Inc. (UP0) stock hit Wall Street targets2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com
Is it too late to sell Ultragenyx Pharmaceutical Inc.Weekly Stock Recap & Daily Profit Maximizing Tips - newser.com
Dosing begins in broader trial of Angelman syndrome therapy - Angelman Syndrome News
Is Ultragenyx Pharmaceutical Inc. stock attractive for long term wealth buildingOil Prices & Free Technical Pattern Based Buy Signals - newser.com
Key metrics from Ultragenyx Pharmaceutical Inc.’s quarterly data2025 Market Overview & Technical Pattern Based Signals - newser.com
Why Ultragenyx Pharmaceutical Inc. stock appeals to dividend seekersJuly 2025 Price Swings & Weekly Breakout Stock Alerts - newser.com
Will Ultragenyx Pharmaceutical Inc. stock remain a Wall Street favorite2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Earnings visualization tools for Ultragenyx Pharmaceutical Inc.2025 Support & Resistance & Weekly Momentum Picks - newser.com
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly results2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - newser.com
Can Ultragenyx Pharmaceutical Inc. (UP0) stock hold up in economic slowdownQuarterly Performance Summary & Daily Volume Surge Signals - newser.com
Is this a good reentry point in Ultragenyx Pharmaceutical Inc.July 2025 Market Mood & Fast Exit and Entry Strategy Plans - newser.com
Is Ultragenyx Pharmaceutical Inc. stock a buy in volatile marketsAnalyst Downgrade & Community Verified Watchlist Alerts - newser.com
Pinnacle Associates Ltd. Sells 29,107 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Chart based analysis of Ultragenyx Pharmaceutical Inc. trends - newser.com
Is Ultragenyx Pharmaceutical Inc. still worth holding after the dipTrade Volume Summary & Verified Chart Pattern Trade Signals - newser.com
Is Ultragenyx Pharmaceutical Inc. stock a top momentum playTrade Entry Summary & High Yield Equity Trading Tips - newser.com
Can Ultragenyx Pharmaceutical Inc. stock sustain revenue growthJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com
How risky is Ultragenyx Pharmaceutical Inc. stock nowJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
Can Ultragenyx Pharmaceutical Inc. stock deliver sustainable ROEJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
Is Ultragenyx Pharmaceutical Inc. stock attractive after correctionWatch List & Long Hold Capital Preservation Plans - newser.com
Y Intercept Hong Kong Ltd Grows Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Is Ultragenyx Pharmaceutical Inc. stock dividend yield sustainablePortfolio Performance Report & Long-Term Investment Growth Plans - newser.com
Will Ultragenyx Pharmaceutical Inc. see short term momentum2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Will Ultragenyx Pharmaceutical Inc. stock benefit from upcoming earnings reports2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.23 a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL) - The Globe and Mail
Ultragenyx doses first subject in study of GTX-102 for angelman syndrome - Clinical Trials Arena
What hedge fund moves indicate for Ultragenyx Pharmaceutical Inc. (UP0) stockTreasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
Emerald Mutual Fund Advisers Trust Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Can Ultragenyx Pharmaceutical Inc. stock weather global recessionJuly 2025 Market Mood & Verified Technical Trade Signals - newser.com
Ultragenyx Pharmaceutical Inc. (RARE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):